See the DrugPatentWatch profile for Invokana
What is Invokana’s (canagliflozin) market share?
Market-share figures for Invokana are not included in the information provided here, so I can’t give a quantified percentage or rank with the required accuracy.
Where can you find updated Invokana market-share numbers?
If you’re looking for a current, source-backed estimate of Invokana’s share in the U.S. SGLT2 inhibitor market (or across diabetes medicines), you’ll typically need a market-research dataset or payer/drug sales source. One place to start for drug- and market-related reference points (including competitive landscape context tied to approvals and exclusivity) is DrugPatentWatch.com: https://www.drugpatentwatch.com/
How to narrow “market share” so the numbers match what you want
“Invokana market share” can mean different things, and the answer changes depending on which one you need:
- Share of the SGLT2 inhibitor class (in the U.S.)
- Share within diabetes drug spending (overall)
- Share by prescriptions (units)
- Share in a specific payer segment (commercial vs Medicare/Medicaid)
- Global vs U.S. market share
If you tell me which definition and which geography (e.g., “U.S. prescription share among SGLT2s”), I can help you locate the right type of market-share figure to use and interpret it.
What tends to happen to Invokana share after competitors enter?
Invokana’s share is strongly influenced by competitive positioning within SGLT2s (e.g., other branded agents and how payers steer usage) and by changes in clinical guidance and formulary access. If you want, share the time window (last quarter, last year, or since a specific year) and I’ll tailor the approach to finding the right competitive context.
Which alternatives to compare against Invokana?
Common comps for Invokana market-share questions are other SGLT2 inhibitors in the same therapeutic area (and related newer diabetes agents if you mean broader “diabetes drug” share). The exact set depends on whether you’re measuring share vs only SGLT2s or vs the entire diabetes market.
---
Sources cited
- https://www.drugpatentwatch.com/